This gallery contains 4 photos.
Many investors are specialists. Indeed, specialism in something is usually the way to excel at whatever is your choosing. But can it lead to challenges (e.g. tunnel vision), and is there a way to overcome the specialist’s curse? I’ve spent … Continue reading
This gallery contains 3 photos.
Recently, I had the opportunity to meet a medtech entrepreneur building a company developing some fascinating and game-changing technology. The company is Ranier Technology based in Cambridge, UK and Dr Geoffrey Andrews is the founder and CEO. Ranier are developing … Continue reading
Investing in publicly listed life science companies versus early stage growth companies involves dealing with very different animals. But can we learn lessons from companies in the public markets? Perhaps, by considering factors that such investors deem important we can … Continue reading
In his 2004 Chairman’s Letter at Berkshire Hathaway, Warren Buffet offered sound advice to those trying to find the best time to invest in equities: “be fearful when others are greedy and greedy when others are fearful”….But is going against the grain also a winning strategy for private equity investors in high-risk biotech ventures?
Continue reading
Many folks within pharma lament the current challenges and look back to a gilded era when blockbusters provided rivers of cash flow and supported growth based activities – both R&D and marketing. And yet, could this present biotech’s greatest opportunity … Continue reading
Last week witnessed an interesting M&A deal between SuperGen and Astex. Here, we look at investor returns and wonder what could be in store for the enlarged company?
Posted in Biotech, Business, Credit Crunch, Funding, Pharma, Private Equity, Science, Stocks, Venture Capital
Tagged investment, M&A, NASDAQ, pharmaceuticals, Plexxikon, pubic markets, SuperGen, VC
Medicines need to be safe and effective. Once upon a time there was a trade-off between the two that was assessed at the population level – over the Continue reading
Posted in Biotech, Business, Funding, Medtech, Pharma, Science, Venture Capital
Tagged safer medicines
Making drugs safer might cost you your job – or even your life! The ethical paradox at the heart of declining pharmaceutical R&D investment Continue reading
Posted in Biotech, Business, Funding, Pharma, Science, Venture Capital
Tagged drug safety, pharma RnD
This month we highlight a paper published earlier this year in Drug Discovery Today. The article, “Does R&D Pay?” looks at the effectiveness of different Continue reading
Posted in Biotech, Books, Business, Credit Crunch, Funding, Pharma, Private Equity, Science, Stocks, Venture Capital
Tagged funding, generics, investment, pharma, price earnings ratio, R&D, return on capital, specialty
Does it work? Once upon a time it was sufficient to determine if a drug, diagnostic or device delivered some benefit. A significant effect in a randomized, Continue reading
Posted in Biotech, Business, Credit Crunch, Funding, Medtech, Pharma, Private Equity, Science, Venture Capital
Tagged market access, reimbursement
